pomalidomide,dexamethasone,abemaciclib,ixazomib,selinexor,enasidenib,erdafitinib,belantamab mafodotin,daratumumab,cobimetinib,venetoclax
roche,takeda,bms,eli lilly,servier,janssen,abbvie,gsk,karyopharm therapeutics
 presents the mydrug study; functional high risk patients with nras/kras mutations treated with cotellic plus ninlaro-pomalyst-dex oral regimen, some deep responses seen. #ims2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.